Research programme: modified chlorotoxin radiotherapeutics - TransMolecular

Drug Profile

Research programme: modified chlorotoxin radiotherapeutics - TransMolecular

Alternative Names: 123I-TM-601; TM-601-I-123; TM-901; TM-902

Latest Information Update: 07 Jan 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TransMolecular
  • Developer Blaze Bioscience; TransMolecular
  • Class Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Diagnostic imaging enhancers; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer
  • Discontinued Solid tumours

Most Recent Events

  • 09 Nov 2015 Chlorotoxin-based infrared imaging agent licensed to Blaze Bioscences
  • 09 Nov 2015 Early research in Cancer (Diagnosis) in USA (unspecified route)
  • 22 Aug 2003 TransMolecular is seeking partnership opportunities for this programme in Solid tumours (http://www.transmolecular.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top